Skip to main content

Company

Biogen

127 published works

  1. The Law and Other Anomalies

    Biogen and Boston’s Life Science Prominence

    By Stephen Honig

    Chris Viehbacher, CEO of Boston biotech giant Biogen, believes that greater Boston has the premier gathering of scientists in medicine in the world.  Addressing today’s gathering of the Boston Chamber…

  2. Big Molecule Watch

    Harrow Re-Launches BYOOVIZ (ranibizumab-nuna) in the United States

    By Grace Truong

    On July 1, 2026, Harrow announced the commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTIS (ranibizumab).   BYOOVIZ was developed by Samsung Bioepis Co., Ltd. (“Samsung Bioepis”). BYOOVIZ was…

  3. Big Molecule Watch

    Sandoz Launches Natalizumab Biosimilar

    By Christopher Cassella

    On November 17, 2025, Sandoz announced the launch of TYRUKO® (natalizumab-sztn) in the United States as the first and only biosimilar for the treatment of relapsing forms of multiple sclerosis.  TYRUKO® was approved…

  4. Big Molecule Watch

    Biogen Ordered to Pay Genentech $88.3 Million in Past Royalties on Cabilly Patents

    By Darlene Staines

    On September 30, 2025, the U.S. District Court for the Northern District of California ordered Biogen MA, Inc. (“Biogen”) to pay Genentech, Inc. (“Genentech”) $88,348,123 in unpaid royalties plus interest.…

  5. Big Molecule Watch

    Harrow Enters Agreement to Commercialize Samsung Bioepis’s Ophthalmology Biosimilars Following Biogen’s Exit

    By Darlene Staines

    On July 17, 2025, Harrow, Inc. (“Harrow”), announced an agreement with Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) to acquire the U.S. commercial rights to two of Samsung Bioepis’s biosimilars, BYOOVIZ®…

  6. Inside Class Actions

    Claims that Drug Manufacturer Paid PBMs to Disrupt Operation of State Generic Substitution Laws not Viable, Says Illinois Court

    By Brandon Gould

    On June 25, an Illinois federal court dismissed an antitrust class action that alleged that branded drug manufacturer Biogen harmed competition by paying Pharmacy Benefit Managers (“PBMs”) not to promote…

  7. Big Molecule Watch

    Biogen Files Suit Against Neurimmune Over Rights to Bispecific Antibody

    By Allegra Padula

    On May 13, 2025, Biogen Inc. and Biogen MA Inc. (“Biogen”) filed a Complaint for Declaratory Judgment and Permanent Injunctive Relief against Neurimmune Holding AG and Neurimmune SubOne AG (“Neurimmune”)…

  8. Big Molecule Watch

    Are Reference Product Sponsors Asserting More Patents in BPCIA Litigation?

    By Huiya Wu|Michael Siekman

    On October 24, 2014, Amgen initiated the first litigation under the Biologics Price Competition and Innovation Act (“BPCIA”), asserting infringement of two patents. Over the last two calendar years, Amgen,…

  9. Big Molecule Watch

    European Commission Approves Samsung Bioepis and Biogen’s Aflibercept Biosimilar

    By Daniel Farraye

    On November 18, 2024, Samsung Bioepis announced that the European Commission (EC) has approved its aflibercept biosimilar, OPUVIZ.  Referencing Regeneron’s biosimilar product EYLEA, OPUVIZ is a 40 mg/mL solution for…

  10. Big Molecule Watch

    Biogen’s TOFIDENCE (tocilizumab) Approved in the EU

    By Alison Siedor

    This week, Biogen announced that the European Commission has approved TOFIDENCE, a tocilizumab biosimilar referencing Roche’s ROACTEMRA.  TOFIDENCE was approved by the FDA in September 2023. TOFIDENCE is an intravenous…